IOXILAN (400 MG)

Absorption

Peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes. This can be accounted for by the dilution in the vascular and extravascular fluid compartments.

Toxicity

Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravascular contrast agents. Administration of any intravascular contrast agent should therefore be postponed in any patient with a known or suspected hepatic or biliary disorder who has recently received a cholecystographic contrast agent.
Other drugs should not be admixed with this product.
Pregnancy Category B

The Uses of IOXILAN (400 MG)

Nonionic iodinated contrast medium. Diagnostic aid (radiopaque medium).

Background

Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs.

Indications

When administered intra-arterially, Ioxilan is indicated for the following diagnostic tests: cerebral arteriography (300 mgI/mL), coronary arteriography and left ventriculography (350 mgI/mL), visceral angiography(350 mgI/mL), aortography(350 mgI/mL), and peripheral arteriography(350 mgI/mL). When administered intravenously, Ioxilan is indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300 and 350 mgI/mL).

Definition

ChEBI: Ioxilan is an amidobenzoic acid.

brand name

Oxilan (Guerbet).

Pharmacokinetics

As with other iodinated contrast agents the degree of contrast enhancement is directly related to the iodine content in the administered dose.

Metabolism

There is no evidence for metabolism.